Genetic effects on carotid intima-media thickness:systematic assessment and meta-analyses of candidate gene polymorphisms studied in more than 5000 subjects by Paternoster, Lavinia et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genetic effects on carotid intima-media thickness
Citation for published version:
Paternoster, L, Martinez-Gonzalez, NA, Charleton, R, Chung, M, Lewis, S & Sudlow, CLM 2010, 'Genetic
effects on carotid intima-media thickness: systematic assessment and meta-analyses of candidate gene
polymorphisms studied in more than 5000 subjects' Circulation. Cardiovascular genetics, vol 3, no. 1, pp.
15-21. DOI: 10.1161/CIRCGENETICS.108.834366
Digital Object Identifier (DOI):
10.1161/CIRCGENETICS.108.834366
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Early version, also known as pre-print
Published In:
Circulation. Cardiovascular genetics
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
  
1942-3268
American Heart Association. All rights reserved. Print ISSN: 1942-325X. Online ISSN: 2010 Copyright ©
Avenue, Dallas, TX 72514
Circulation: Cardiovascular Genetics is published by the American Heart Association. 7272 Greenville
DOI: 10.1161/CIRCGENETICS.108.834366
 2010;3;15-21; originally published online December 11, 2009;Circ Cardiovasc Genet
Steff Lewis and Cathie L.M. Sudlow
Lavinia Paternoster, Nahara A. Martinez-Gonzalez, Rebecca Charleton, Mabel Chung,
Subjects
Meta-Analyses of Candidate Gene Polymorphisms Studied in More Than 5000 
Genetic Effects on Carotid Intima-Media Thickness : Systematic Assessment and
 
 
 
 http://circgenetics.ahajournals.org/content/3/1/15.full
on the World Wide Web at: 
The online version of this article, along with updated information and services, is located
 
.DC1.html 
http://circgenetics.ahajournals.org/content/suppl/2009/12/11/CIRCGENETICS.108.834366
Data Supplement (unedited) at: 
 http://www.lww.com/reprints
Reprints: Information about reprints can be found online at
 
 journalpermissions@lww.com
410-528-8550. E-mail:
Health, 351 West Camden Street, Baltimore, MD 21201-2436. Phone: 410-528-4050. Fax: 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters Kluwer
 
 http://circgenetics.ahajournals.org/site/subscriptions/
Subscriptions: Information about subscribing to Circulation: Cardiovascular Genetics is online at
 at UNIVERSITY EDINBURGH on June 11, 2013circgenetics.ahajournals.orgDownloaded from 
Genetic Effects on Carotid Intima-Media Thickness
Systematic Assessment and Meta-Analyses of Candidate Gene
Polymorphisms Studied in More Than 5000 Subjects
Lavinia Paternoster, MSc; Nahara A. Martinez-Gonzalez, MSc; Rebecca Charleton, MBChB;
Mabel Chung, MBChB; Steff Lewis, PhD; Cathie L.M. Sudlow, DPhil, FRCPE
Background—Carotid intima-media thickness (CIMT) is highly heritable and associated with stroke and myocardial
infarction, making it a promising quantitative intermediate phenotype for genetic studies of vascular disease. There have
been many CIMT candidate gene association studies, but no systematic review to identify consistent, reliable findings.
Methods and Results—We comprehensively sought all published studies of association between CIMT and any genetic
polymorphism. We obtained additional unpublished data and performed meta-analyses for the 5 most commonly studied
genes (studied in at least 2 studies in a total of 5000 subjects). We used a 3-step meta-analysis method: meta-analysis
of variance; genetic model selection; and random effects meta-analysis of the mean CIMT difference between
genotypes. We performed subgroup analyses to investigate effects of ethnicity, vascular risk status, and study size. We
accounted for potential reporting bias by assessing qualitatively the possible effects of including unavailable data.
Polymorphisms in 3 of the 5 genes (apolipoprotein E, angiotensin I converting enzyme, and 5,10-methylenetetrahy-
drofolate reductase) had an apparent association with CIMT, but for all these, we found evidence of small study bias.
Apolipoprotein E 2/3/4 was the only polymorphism with a persistent, statistically significant but modest association
when we restricted analysis to larger studies (1000 subjects).
Conclusions—Of the most extensively studied polymorphisms, apolipoprotein E 2/3/4 is the only one so far with a
convincing association with CIMT. Larger studies than have generally been performed so far may be needed to confirm
the associations identified in future genome-wide association studies, and to investigate modification of effect according
to characteristics such as ethnicity and vascular risk status. (Circ Cardiovasc Genet. 2010;3:15-21.)
Key Words: carotid arteries  genetics  meta-analysis
Studying intermediate, quantitative traits is a potentiallyuseful approach to identify genetic risk factors for ische-
mic stroke and ischemic heart disease.1 Carotid intima-media
thickness (CIMT) is an intermediate phenotype for early
atherosclerosis, is a strong predictor of future vascular events,
including myocardial infarction and ischemic stroke, and is
significantly greater in large artery (atherothrombotic) than
small artery ischemic stroke.2–4 Estimates of its heritability
range from 30% to 86%.5–7
Clinical Perspective on p 21
There have been many studies on the effects of a range of
candidate genes on CIMT, the results of which could provide
useful insights into genetic influences on atherothrombotic
disease and on large artery ischemic stroke and ischemic
heart disease. We aimed to identify all published studies of
the influence of any genetic polymorphism on CIMT and, for
the most commonly studied polymorphisms, to carry out
detailed methodological appraisals and meta-analyses of rel-
evant studies. In doing so, we aimed to establish which
candidate gene polymorphisms have been most extensively
studied, and of these, which have shown reliable associations
with CIMT, and how studies in this area might be improved
in the future.
Methods
Identification of Studies
We used a comprehensive, 2-stage search strategy. In stage 1, we
used an electronic search in Medline (1966 to end of 2007) and
Embase (1980 to end of 2007) combining general genetics terms
with terms for CIMT and carotid atheroma (see Methods in the
online-only Data Supplement). From an initial screening of the titles,
abstracts, and occasionally full articles, we identified all potentially
relevant studies.
In stage 2, we carried out a series of supplementary searches in
Medline and Embase for genetic polymorphisms that had been
studied in at least 2 studies (because of the recognized importance of
Received November 8, 2008; accepted August 21, 2009.
From the Division of Clinical Neurosciences (L.P., N.A.M.-G., S.L., C.L.M.S.), Centre for Molecular Medicine, Institute of Genetics and Molecular
Medicine (C.L.M.S.), and Medical School (R.C., M.C.), University of Edinburgh, Edinburgh, United Kingdom.
The online-only Data Supplement is available at http://circgenetics.ahajournals.org/cgi/content/full/CIRCGENETICS.108.834366.
Correspondence to Cathie Sudlow, DPhil, FRCPE, Division of Clinical Neurosciences, Western General Hospital, Edinburgh EH4 2XU, United
Kingdom. E-mail cathie.sudlow@ed.ac.uk
© 2010 American Heart Association, Inc.
Circ Cardiovasc Genet is available at http://circgenetics.ahajournals.org DOI: 10.1161/CIRCGENETICS.108.834366
15
 at UNIVERSITY EDINBURGH on June 11, 2013circgenetics.ahajournals.orgDownloaded from 
the need for independent replication of genetic associations) in a total
of 5000 subjects, combining gene-specific terms with terms for
CIMT and carotid atheroma, to ensure that we had identified all
potentially relevant articles for the selected polymorphisms (see
Methods in the Data Supplement). We used the subject-number
cutoff of 5000 to restrict our detailed analysis to a manageable
number of polymorphisms for which results were likely to be the
most precise and reliable.
We sought studies in all languages, obtaining translations where
necessary. We obtained full articles for all potentially relevant
studies of the selected polymorphisms, as well as for relevant
reviews, and checked the reference lists of these for any further
relevant studies.
We included in our analyses any study that had assessed the
association between variation in one of the selected polymorphisms
and a measure of the thickness of the intima-media of the carotid
artery. We excluded data on associations with IMT of arteries other
than the carotid, with frank atheroma or plaque in the carotid or other
arteries, or with change or rate of change in IMT. We avoided double
counting by using only the largest available published dataset from
any study described in 1 published article.
Data Extraction
We extracted information from the articles relevant to each selected
study on year of publication; total number of subjects studied;
country in which the study was conducted; ethnicity of the subjects;
types of subjects studied (eg, healthy volunteers, subjects sampled
from the general population, subjects with hypertension, or with
diabetes); mean age and gender distribution of the subjects; candi-
date genes and specific polymorphisms studied; whether genotypes
were, after calculation or from published data, in Hardy-Weinberg
equilibrium; method of CIMT measurement, where possible select-
ing measurement of the mean of the far wall of the left and right
common carotid artery or as close to that as could be achieved; and,
for each genotype, number of subjects, and their mean CIMT (and
SD). Wherever possible, we treated studies that had presented data
separately for groups of subjects defined by criteria such as ethnicity
or presence of specific medical condition as separate substudies.
Two authors (L.P. and one among N.A.M.-G., R.C., or M.C.)
independently reviewed study eligibility and extracted the informa-
tion and data from each study, resolving disagreements and uncer-
tainties by discussion and mutual consensus, involving another
author (C.L.M.S. or S.L.) if necessary. If key information or data
were not presented in the relevant publications, we sought them
directly from the authors of the relevant studies.
Statistical Analysis
We used a 3-step approach to investigate the association with CIMT
of each genetic polymorphism studied:
1. We first determined whether there was evidence of an overall
association between genotype and CIMT, by carrying out a
meta-analysis of variance (meta-ANOVA) of CIMT, with
study and genotype as categorical variables, weighting studies
by the inverse of the square of the SEM CIMT.8
2. When we found a statistically significant (P0.05) overall
association from meta-ANOVA, we went on to determine
which genetic model (recessive, codominant, or dominant)
should be used to determine the size and nature of the
association. We used a regression method to estimate the value
 (and its CI), allowing us to select the most appropriate
genetic model for meta-analysis, depending on whether  was
closest to 0 (recessive), 0.5 (codominant), or 1 (dominant; see
Methods in the Data Supplement). We did not perform further
analyses for any polymorphism not reaching statistical signif-
icance at the meta-ANOVA stage.
3. Using the selected genetic model, we calculated the study-
specific and random effects pooled mean differences in CIMT
between genotype groups (CIMT mean difference per single
allele change for the codominant model).
For the apolipoprotein E (APOE) genetic polymorphism, the 3
commonly encountered alleles (2, 3, and 4) make up 6 genotypes.
For genetic model selection and meta-analysis, we adopted the
common convention of grouping these as E2 (22 or 23), E3
(33), and E4 (44 or 34), such that a codominant model
implied equal differences in CIMT between E2, E3, and E4
genotypes.
We used the I2 statistic to assess heterogeneity between studies,
where I2 estimates the percentage of variation between studies that
cannot be attributed to chance.9 We performed prespecified subgroup
analyses to assess the effects of study size (above or below the mean
number of subjects per eligible study or substudy and in a post hoc
analysis above or below 1000 subjects), ethnicity (Eastern Asian,
Southern Asian, white, or black), and high or low vascular risk status
(where studies among subjects with a history of vascular disease or
included on the basis of one or more vascular risk factors such as
hypertension or diabetes were considered high risk, and studies
among healthy volunteers or those from the general population were
considered low risk). We used 2 tests to assess the significance of
differences between subgroups in the size of the association between
genotype and CIMT. We assessed the potential for publication bias
through subgroup analyses based on study size (above) and visual
examination of funnel plots.
We carried out all statistical analyses in Stata version 7.0. We
were unable to include in formal meta-analyses several otherwise
eligible studies for which the necessary data remained unavailable
even after attempts to obtain it from the studies’ authors. For each
polymorphism selected for analysis, we quantified the proportion of
all subjects from eligible studies for whom data were unavailable for
meta-analysis. Because qualitative statements about the presence or
absence of an association between genotype and CIMT were
generally available from the relevant articles for the studies with
incomplete data, we attempted informally to assess how our results
and overall conclusions might have been affected if we had been able
to include these studies in our meta-analyses.
Results
Identification and Selection of Genetic
Polymorphisms and Studies for Meta-Analyses
Our stage 1 search strategy yielded 2319 articles, 384 of
which seemed to be potentially relevant from titles and
abstracts. Polymorphisms in 5 genes (APOE, apolipoprotein
E; ACE, angiotensin I converting enzyme; MTHFR, 5,10-
methylenetetrahydrofolate reductase; NOS3, nitric oxide syn-
thase 3 [endothelial cell]; ADD1, adducin 1) had been studied
in at least 2 studies in a total of 5000 subjects. We selected
these genes for stage 2 gene-specific searching and analyses.
For each of the 5 selected genes, Table 1 gives summary
information on the polymorphisms studied, the function of
their protein products, and the numbers of relevant studies
(and subjects), together with information on numbers of studies
(and subjects) that could not be included in meta-analyses
because the necessary data were unavailable.
We identified 95 independent studies (77 118 subjects) that
analyzed the association between CIMT and a polymorphism
or polymorphisms in 1 of the 5 genes of interest (Supplemen-
tal references W1–W95). Twenty-nine studies (including
12 982 subjects) did not have all the necessary data available
for analysis in the relevant published articles (supplemental
references W4, W5, W15, W16, W25, W27, W29, W36, W47,
W50, W53, W54, W59, W61, W63, W64, W67, W69, W70,
W72, W76, W78, W80, W82, W84, W86, W92, and W94), and
authors from 9 of these were able to provide us with additional
unpublished data (Supplemental references W15, W16, W27,
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W29, W59, W76, W78, W80, and W84), enabling us to retrieve
24% of the unavailable data (5457/12 982 subjects).
Characteristics of Included Studies
The summary characteristics of all relevant studies for the 5
selected genes are shown in supplemental Table I. Sample
sizes ranged from 47 to 9304. White subjects from Europe,
Australia, and the United States made up the majority of
subjects; Eastern Asian subjects were mostly from China,
Japan, and Taiwan; and 1 study included Southern Asian
subjects. One study was carried out in black Americans.
Subjects were mostly middle aged to elderly. Most were
from population samples or healthy volunteers, but some
were selected groups of patients at high vascular risk.
Genotypes were mostly in Hardy-Weinberg equilibrium, and
where they were not, the subjects were generally selected
patient groups for which Hardy-Weinberg proportions would
not necessarily be expected. CIMT measurement methods
varied between studies, but the majority measured the far wall
of the common carotid artery.
Tests for Overall Association and Selection of
Genetic Models
Table 2 shows the results of the 3-step meta-analysis for the
5 selected genes. Meta-ANOVA found an overall association
between genotype and CIMT at P0.05 for only 3 poly-
morphisms: APOE (2/3/4), ACE (I/D), and MTHFR (677
C/T). Linear regression showed that APOE (2/3/4) and
ACE (I/D) should be analyzed according to a codominant
genetic model (0.4 and 0.5, respectively). For MTHFR
(677 C/T),  was estimated to be 0.2 (95% CI, 0.1 to 0.4).
Although the estimated 95% CI did not include any of the
expected values (0, 0.5, or 1), we analyzed the data using a
recessive model, because 0.2 is closest to 0.
Meta-Analyses of Polymorphisms in APOE, ACE,
and MTHFR
We found 30 relevant studies (36 substudies, 32 995 subjects)
for APOE (2/3/4). Full data for meta-analysis were
unavailable in relevant publications or from the authors for 3
studies (742 subjects, 2% of subjects; supplemental references
W4, W5, and W25). Meta-ANOVA yielded a significant overall
association between APOE and CIMT (P0.001), with a pooled
random effects estimate of the difference in mean CIMT per
step from E2 to E3 or from E3 to E4 genotypes of 25 m
(95% CI, 17 to 33; Table 2 and supplemental Figure I).
We found 39 relevant studies (43 substudies, 20 105 subjects)
for ACE (I/D). Full data for meta-analysis were unavailable for
9 studies (3067 subjects, 15% of subjects; supplemental refer-
ences W25, W36, W47, W50, W53, W54, W61, W63, and
Table 1. Five Selected Genes With Polymorphisms Studied for Association With CIMT in >5000 Subjects:
Function of Gene Protein Products and Number of Studies (and Subjects) Identified
Gene (Polymorphism)*
No. of Studies/
Substudies (Subjects)
in Analysis†
No. of Studies
Fulfilling Inclusion
Criteria (Subjects)
No. of Studies
(Subjects) With
Data Available for
Analysis
No. of Studies (Subjects)
With Incomplete Data,
Excluded From Analysis
APOE (2, 3, 4) Lipid metabolism 30 (32 995) 27 (32 253) 3 (742)
ACE (I/D) Renin-angiotensin system
(BP/fluid balance)
39 (20 105) 30 (17 038) 9 (3067)
MTHFR (677 C/T) Homocysteine metabolism 20 (10 487) 13 (7945) 7 (2542)
NOS3 (Glu298Asp) Vascular smooth muscle
endothelial function
12 (7475) 6 (4390) 6 (3085)
ADD1 (Gly460Trp) Endoskeletal protein involved
in BP regulation
4 (6056) 3 (5636) 1 (420)
APOE indicates apolipoprotein E; ACE, angiotensin I–converting enzyme; MTHFR, 5,10-methylenetetrahydrofolate reductase; NOS3,
nitric oxide synthase 3; ADD1, adducin 1 (); BP, blood pressure.
*Polymorphisms defined using their common name, 677 C/T notation denotes DNA base change, and Glu298Asp denotes amino
acid change.
†Gene functions obtained from UniProtKB/Swiss-Prot database.
Table 2. Results of the 3-Step Meta-Analysis of the Association Between CIMT and Polymorphisms in the
5 Selected Genes
Gene
No. of Studies
(Subjects)
in Analyses
Step 1
Meta-ANOVA
P Value
Step 2
Step 3
Random Effects Pooled
Mean CIMT Difference Between
Genotypes With Selected
Model, m (95% CI) (95% CI)
Selected Genetic
Model
APOE (2, 3, 4) 32 (32253) 0.001 0.4 (0.3 to 0.6) Codominant 25 (17 to 33)
ACE (I/D) 34 (17038) 0.005 0.5 (0.4 to 0.6) Codominant 14 (5 to 22)
MTHFR (677 C/T) 15 (7945) 0.02 0.2 (0.1 to 0.4) Recessive 29 (0 to 58)
NOS3 (Glu298Asp) 8 (4390) 0.3 … … …
ADD1 (Gly460Trp) 3 (5636) 0.7 … … …
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W64). Meta-ANOVA yielded a significant overall association
between ACE and CIMT (P0.005), the pooled estimate of the
per allele (D) difference in mean CIMT being 14 m (95% CI,
5 to 22; Table 2 and supplemental Figure II).
We found 20 relevant studies (22 substudies, 10 487
subjects) for MTHFR (677 C/T). Full data for meta-analysis
were unavailable for 7 studies (2542 subjects, 24% of
subjects; supplemental references W50, W63, W67, W69,
W70, W72, and W82). Meta-ANOVA yielded a significant
overall association between MTHFR and CIMT (P0.02).
The pooled estimate of the difference between TT and CT/CC
genotypes was 29 m (95% CI, 0 to 58; Table 2 and
supplemental Figure III).
For each of these 3 genetic polymorphisms, there was
substantial heterogeneity between studies (I2 values 80%;
supplemental Figure I through III). The results of prespecified
subgroup analyses to investigate possible causes of this
heterogeneity were strikingly similar for all 3 polymorphisms
(Figure). We found substantially larger pooled mean CIMT
differences among Eastern Asian compared with white pop-
ulation (the subgroup difference was highly significant for
APOE), in high-risk populations compared with low-risk
populations (subgroup differences clearly significant for all 3
polymorphisms), and in smaller compared with larger studies
(subgroup differences clearly significant for all 3 poly-
morphisms), suggesting the existence of small study bias. For
each polymorphism (especially APOE and ACE), there was
less heterogeneity between the results of the larger studies.
Study size could explain the apparent difference in size of
association between different ethnicities and risk groups,
because studies in high-risk populations and among Eastern
Asian subjects were on average much smaller than among
low-risk populations and white subjects (Figure). In keeping
with the results of subgroup analyses based on study size,
funnel plots of the study-specific mean difference versus its
standard error were asymmetrical for all 3 polymorphisms,
suggestive of small study bias, most likely publication bias.
Focusing attention on just the larger (and presumably more
reliable) studies, an association between CIMT and APOE
remained, albeit much smaller than the overall pooled esti-
mate, with an estimated mean CIMT difference of 8 m (95%
CI, 6 to 11) per step from E2 to E3 to E4 genotype groups, but
associations between CIMT and both ACE (I/D) and MTHFR
(677 C/T) were smaller and no longer statistically significant
(for ACE, mean CIMT difference per additional D allele:
4 m, 95% CI, 0 to 8; for MTHFR, mean CIMT difference
between TT and CT/CC: 9 m, 95% CI, 32 to 13). In a
further post hoc subgroup analysis, we restricted analyses to
studies in 1000 subjects and found a similar, significant
result for APOE and similar, nonsignificant results for ACE
and MTHFR (data not shown).
Of the 3 studies with data unavailable for the APOE meta-
analysis, one found an association between E4 genotypes and
higher CIMT (W4), another found a similar association in the
nondiabetic subgroup only (W5), and the third found no asso-
ciation (W25). All 3 were small (66, 206, and 470 subjects) and
so would not have contributed to the analysis including only
larger studies (supplemental Figure I).
Most of the 9 studies with data unavailable for the ACE
meta-analysis reported no association. Three would have
contributed to our “larger studies” analysis, using the mean
study size cutoff criterion (W25, W61, and W63). Of these, 2
found that the D allele was associated with increased CIMT,
so their inclusion could potentially have strengthened the
association between ACE and CIMT. However, none of the
studies with data unavailable for meta-analysis would have
been large enough to merit inclusion in our analysis of studies
including 1000 subjects (supplemental Figure II).
Of the 7 studies with data unavailable for the MTHFR
meta-analysis, 2 were larger than the mean study size cutoff
for the study size subgroup analysis (W63 and W69). The
smaller of these found an association between MTHFR (677
C/T) and CIMT whereas the other did not, and so their
inclusion would seem unlikely to materially alter the results
of any of the MTHFR analyses (supplemental Figure III).
Other Selected Genes
There was no association between CIMT and polymorphisms
in nitric oxide synthase 3 or adducin 1 (Table 2). Although
the proportion of data unavailable for meta-analysis was
40% for nitric oxide synthase 3 (Table 1), almost all studies
with unavailable data reported either no association or asso-
ciation only in a particular subgroup (eg, in males or black
diabetics only). Thus, it seems unlikely that the inclusion of
these data would have materially affected the results for these
polymorphisms.
Other Potential Genes of Interest
Our search strategy identified polymorphisms in 140 genes
that had been studied for an association with CIMT, but less
than half of these had been assessed in 1 study. Of those
studied in 5000 subjects, 19 genetic polymorphisms had
been studied in a total of3000 to 5000 subjects, a further 53
in a total of 1000 to 3000 subjects, and a further 68 in an
estimated total of 1000 subjects. Excluding those included
in our meta-analyses, for 46 genetic polymorphisms, the
largest study done had 1000 subjects (and so could,
according to the results of our analyses based on study size,
be considered reliable), but in no more than a handful of cases
was the genetic polymorphism assessed in at least 2 studies
including 1000 subjects each. Many of the genetic poly-
morphisms studied but not included in our meta-analyses
showed preliminary evidence for an association with CIMT,
but most if not all of these would need replication in much
larger samples before the results could be considered reliable.
For many others, the study or studies performed were too
small reliably to detect effects of moderate size.
Discussion
Although there have been narrative reviews of the genetics of
CIMT,10 to our knowledge, there has not previously been an
attempt to review the evidence for genetic associations with
this phenotype systematically. Narrative reviews draw atten-
tion to exciting new findings and may stimulate new research
but may selectively emphasize results of particular studies,
and so can sometimes be misleading.11
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Our systematic review identified 140 genes studied as
candidates for association with CIMT. We reviewed in detail
95 independent studies of the association between CIMT and
polymorphisms in the 5 most commonly studied genes and
found clear evidence of an association for only one of these.
Polymorphisms in the APOE, ACE, and MTHFR genes all
showed a significant association with CIMT in meta-
ANOVA analysis. But, of these, APOE (2/3/4) was the
APOE
A  Ethnicity of subjects
Mean CIMT difference in µm (95% CI)No. sub-
studies
No.
subjects
Mean
study size
Within group 
heterogeneity (I²)
Between group 
heterogeneity (χ²)
ACE
E.Asian
White
Black
E.Asian
White
13 (6 to 19)
12 (6 to 18)
40 (4 to 76)
10 (1 to 19)
67 (24 to 110)
22
1
6
28
9
27524
3187
4730
12308
1542
1251
3187
788
440
171
60
-
87
75
82
p<0.001
p=0.2
-100 0 100
MTHFR
E.Asian
White
53 (-11 to 117)
20 (-27 to 66)
5
9
4436
3226
887
358
87
84
p=0.1
S.Asian 95 (-16 to 207)1 283 283 -
51 (22 to 81)
Mean CIMT difference in µm (95% CI)
B  Vascular risk status of subjects
APOE
High 16 2709
No. sub-
studies
No.
subjects
169
Mean
study size
82
Within group 
heterogeneity (I²)
Between group 
heterogeneity (χ²)
10 (5 to 15)
26 (6 to 46)
4 (-2 to 9)
54 (-1 to 109)
ACE
MTHFR
Low
High
Low
High
16
17
17
7
29544
2707
14331
2327
1847
159
843
332
55
82
28
78
p<0.001
p<0.001
p=0 002
-100 0 100
C  Study size
16 (-25 to 57)
No. sub-
studies
No.
subjects
Mean
study size
Low
Mean CIMT difference in µm (95% CI)
8 5618 702 85
.
Within group 
heterogeneity (I²)
Between group 
heterogeneity (χ²)
APOE
ACE
Small (<900)
Large (>900)
Small (<450)
Large (>450)
26
6
29
5
4932
27231
4777
12261
190
4539
165
2452
43 (24 to 61)
8 (6 to 11)
16 (5 to 28)
4 (0 to 8)
11
80
0
81
p<0.001
p=0.002
-100 0 100
MTHFR
Small (<500)
Large (>500)
10
5
1937
6008
194
1202
70 (4 to 136)
-9 (-32 to 13)
85
62
p<0.001
Figure. Meta-analyses of associations with CIMT of APOE (2/3/4), ACE (I/D), and MTHFR (677 C/T) by subgroup, according to ethnicity (A),
according to the vascular risk status (B), and according to study size (C) (above and below the mean study size for each gene). The data are ana-
lyzed according to a codominant genetic model for APOE and ACE and a recessive model for MTHFR. Diamonds represent random effects pooled
mean differences and the width of each diamond represents the 95% CI. The horizontal axis refers to the mean difference between genotype
groups (E4E3 and E3E2) for APOE, the per D allele increase for ACE, and the difference between TT and CT/CC for MTHFR.
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only polymorphism whose association withstood restricting
analysis to larger studies only, suggesting that although there
almost certainly is an association, its size is overestimated in
the literature because of small study bias. Our subgroup
analyses suggest that the apparent associations with CIMT of
ACE and MTHFR, and apparent modification of genetic
effects according to ethnicity and vascular risk status, may
well be due to small study bias. The 95% CI from analyses
restricted to the larger and more reliable studies of the
relevant polymorphisms in these genes would suggest that,
for both ACE I/D and MTHFR 677 C/T, an association with
CIMT remains possible, but is unlikely to be larger in
magnitude than 8 m per additional D allele for ACE I/D and
could range between approximately 35 and 13 m for
MTHFR 677 TT versus CT/CC.
Our study has some particular strengths. We used a series
of explicit, predefined methods to select genes for further
investigation, to assess whether there was an overall associ-
ation between genotype and CIMT, and to choose the most
appropriate genetic model for meta-analysis. We also sought
additional unpublished data where it was unavailable in
publications and considered the implications of any data that
remained unavailable for analysis. Publications identified by
our search in which the association between a genetic
polymorphism and CIMT was not the main feature of the
article tended not to identify an association and not to report
results in full, although sometimes reported positive results
for particular subgroups. Thus, we identified and accounted
for reporting bias, where positive results tend to be high-
lighted and reported in more detail than negative ones.
Previous meta-analyses in stroke genetics have used adequate
reporting of data within publications as a criterion for
inclusion,12 which might make them prone to reporting bias.
Two linkage studies have identified quantitative trait loci
for CIMT. One reported a maximum LOD score of 4.1 at 161
cM on chromosome 12 and subsequently found evidence of
association with an atherosclerosis candidate gene (SCARB1,
a high density lipoprotein receptor, cell-surface glycoprotein)
from the region of linkage.13 The other identified 2q33-35 as
a region with significant linkage (LOD3.08), including the
NOSTRIN, IGFBP2, and IGFBP5 genes, none of which have
yet been independently tested for an association with CIMT.14
In the current era of genome-wide association studies,
further promising candidates for CIMT are likely to emerge
in the near future. The findings of our systematic review
suggest that, if CIMT is to fulfill its promise as an interme-
diate phenotype that will improve our understanding of the
genetics of vascular diseases, studies to confirm associations
with promising candidates identified in genome-wide studies
may have to be very large. For example, if other poly-
morphisms influencing CIMT have effect sizes similar to that
of APOE, then studies would need to be powered to detect
between-genotype differences in CIMT of as small as
10 m (the approximate effect size found by pooling data
from the larger, more reliable studies). Taking estimates of
the population mean and standard deviation of CIMT from a
recent relevant review (mean, 700 m; SD, 160 m),2 a
sample size of 6000 subjects would be needed for 80%
power at P0.05 (and of almost 12 000 subjects for 90%
power at P0.01) to detect a per-genotype mean CIMT
difference of 10 m in a codominant model, assuming a
minor allele frequency of 0.2. Estimated sample sizes are
larger with more stringent power and significance criteria or
for polymorphisms with a lower minor allele frequency but
are smaller with a higher minor allele frequency, or if we only
want reliably to detect larger CIMT differences of up to, say,
100 m. For example, reliable detection (90% power at
P0.01) of a per-genotype mean CIMT difference of 100 m
assuming a minor allele frequency of 0.05 would need 400
subjects (supplemental Table II). To set this in context, an
increase in CIMT of 100 m is associated with an increased
future risk of myocardial infarction and stroke of 15% and
18%, respectively.2 At any minor allele frequency, more than
2000 subjects would be required reliably to detect a CIMT
difference of 25 m (supplemental Table II), and because it
is recommended that findings are replicated in studies that are
larger than the discovery dataset, a total of 5000 subjects
would be required to detect and confirm such effects confi-
dently. However, our study’s stringent cutoff of 5000 subjects
for inclusion means that we may have missed genetic poly-
morphisms with effect sizes much larger than this.
So far, among the most extensively studied genetic poly-
morphisms, APOE 2/3/4 is the only one to have shown a
convincing association with CIMT, with E4 genotypes asso-
ciated with an increase and E2 genotypes with a decrease in
CIMT. This is consistent with meta-analyses showing an
association between the APOE polymorphism and ischemic
heart disease,15 our previous meta-analysis of the association
between APOE and stroke subtypes, which suggested that
APOE E4 genotypes may be specifically associated with the
large artery subtype of stroke but not with other ischemic
subtypes,16 with our previous meta-analysis of APOE and
CIMT that used less sophisticated statistical methods,17 and
with our meta-analysis of APOE and white matter hyperin-
tensities on brain imaging (a quantitative phenotype linked to
small vessel disease lacunar stroke), which did not identify an
association.18
The genes we reviewed here were those most commonly
studied, mainly because they are key genes in known candi-
date pathways for vascular disease. This method of selecting
genes is limited by current knowledge. Recent successes with
the genome-wide association approach show the potential for
hypothesis-free methods to identify candidate genes in novel
pathways,19 which, if confirmed in studies of adequate size,
may lead to new insights into the causes of and treatments for
complex disease, including CIMT and so atherothrombotic
vascular diseases.
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CLINICAL PERSPECTIVE
Carotid intima-media thickness (CIMT) is a measure of subclinical atherosclerosis, is associated with future risk of
myocardial infarction and stroke, and is highly heritable. Studies of genetic factors influencing CIMT may identify genes
that alter risk of ischemic heart disease and stroke, in particular large artery ischemic stroke, thereby helping us to better
predict the risk of developing these clinical conditions and better understand their aetiology. We systematically identified
and performed meta-analyses of all studies of the association of CIMT with variation in any gene that had been studied
in 2 studies with a total of 5000 individuals. We found only 1 gene (apolipoprotein E, which affects cholesterol levels)
that had a robust association with CIMT, but the magnitude of the association was quite small, limiting its utility in clinical
risk prediction. Genome-wide studies and large confirmatory candidate gene studies are needed for reliable identification
of genes associated with CIMT.
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SUPPLEMENTAL MATERIAL 
 
Supplemental methods 
 
 
Stage 1 Medline search strategy* 
 
1     exp carotid artery diseases/ge 
2     exp carotid arteries/ 
3     (carotid adj8 (atherosclero$ or stenos$ or plaque$ or imt or cimt or arteriosclero$ or intima media$ or 
intimal media$ or ultrasound or sclero$ or atheroma$ or wall or thick$)).tw. 
4     2 or 3 
5     exp genetics/ or exp genotype/ or exp inheritance patterns/ or exp "linkage (genetics)"/ or exp 
phenotype/ or exp "variation (genetics)"/ or chromosomes/ or exp genes/ or exp genome/ 
6     (polymorphi$ or genotyp$ or gene or genes or genetic$ or allel$ or mutat$).tw. 
7     5 or 6 
8     4 and 7 
9     1 or 8 
10     limit 9 to humans 
 
* we used a similar, appropriately adapted strategy for Embase 
 
 
 
Stage 2 Medline search strategy for MTHFR* 
 
1     exp carotid artery diseases/ge 
2     exp carotid arteries/ 
3     (carotid adj8 (atherosclero$ or stenos$ or plaque$ or imt or cimt or arteriosclero$ or intima media$ or 
intimal media$ or ultrasound or sclero$ or atheroma$ or wall or thick$)).tw. 
4     1 or 2 or 3 
5     exp "Methylenetetrahydrofolate Reductase (NADPH2)"/ge [Genetics] 
6     (MTHFR or methylenetetrahydrofolate or c677t or nadph2).tw. 
7     methylene tetrahydrofolate.tw. 
8     5 or 6 or 7 
9     4 and 8 
 
* we used a similar, appropriately adapted strategy for the other genes and for Embase 
 
Details of method of genetic model selection 
We describe the process of genetic model selection by denoting the genotypes for a particular 
polymorphism with two possible alleles as aa, ab, and bb, where a is the common allele and b is the rare 
allele.  For each study, i, we calculated MD1i, the difference in mean CIMT for subjects with ab versus aa 
genotypes, and MD2i , the difference in mean CIMT for subjects with bb versus aa genotypes.  We 
performed a weighted linear regression of MD1i on MD2i. weighting each study by the inverse of the 
square of the mean of the standard errors of MD1i and MD2i for that study, and forcing the regression line 
to pass through the  origin (0,0).  The gradient of the regression line estimated the value λ (and its 
confidence interval, CI), allowing selection of the most appropriate genetic model for meta-analysis, 
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depending on whether λ was closest to 0 (recessive, bb versus ab/aa), 0.5 (co-dominant, bb versus ab 
versus aa, giving mean CIMT per single allele change), or 1 (dominant, bb/ab versus aa).   
Where there was only one study for a particular selected gene, meta-ANOVA in step one was replaced by 
ANOVA, and  was simply calculated as MD1/MD2 for that study.  
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Supplemental tables 
 
Supplemental table 1.  Characteristics of studies included for each of the 5 selected genes (as shown in Table 1) 
 
Study (first author & 
publication year) 
No. of 
subjects Country 
Ethnicity of 
subjects Type of subjects Mean age ± SD % male 
Vascular 
risk status HWE Carotid segment 
Near/far 
carotid wall 
Right/left 
carotid Mean/max 
 
            
APOE 
            
Terry 1996 W1 254 US White Coronary angiography referrals 59±9 50 High  CCA Both Both Mean of max of 4 sites 
Cattin 1997 W2 254 Italy White Population sample 53±7 46 Low  CCA Both Both Mean of right and left 
Kogawa 1997a W3 349 Japan E.Asian NIDDM patients 60±11 58 High  CCA/BIF * * Mean of 3 sites 
Kogawa 1997b W3 231 Japan E.Asian Non-diabetic subjects 51±11 37 Low  CCA/BIF * * Mean of 3 sites 
Olmer 1997W4 ‡ 66 France White Hemodialysis patients 50±15 50 High  CCA Far Both Mean of 3 each side 
Vauhkonen 1997a W5 § 83 Finland White NIDDM patients 56±7 52 High  CCA/BIF Far Both Mean of max of 4 sites 
Vauhkonen 1997b W5 § 123 Finland White Population sample 54±5 46 Low  CCA/BIF Far Both Mean of max of 4 sites 
Sass 1998 W6 144 France White Population sample 41±4 52 Low * CCA * Both Mean of 2 each side 
Zhang 1998 W7 52 China E.Asian CHD patients 57±8 100 High  CCA/BIF/ICA Far Both Mean of 8 sites 
Guz 2000 W8 261 Turkey White Hemodialysis patients 46±15 57 High  CCA * Both Mean of 3 each side 
Hanon 2000 W9 312 France White Patients with vascular risk factors/disease 49±12 53 High * CCA Far Right One measurement 
Horejsi 2000 W10 112 Czech Republic White Lipoprotein disorder patients 53±* 45 High * CCA Far * Mean of max of 3 sites 
Ilveskoski 2000 W11 189 Finland White Population sample 54±3 100 Low  CCA Both Both Max of 4 sites 
Slooter 2001 W12 5264 Netherlands White Population sample 69±9 41 Low  CCA Far Both Mean of left and right 
Tabara 2001 W13 202 Japan E.Asian Population sample 70±9 32 Low  CCA Far Right Mean of 3 sites 
Haraki 2002 W14 95 Japan E.Asian Healthy subjects 50±8 100 Low  CCA Far Right Mean of 9 sites 
Karvonen 2002a W15 ‡ 258 Finland White Hypertensive patients 51±6 100 High  CCA/BIF/ICA Far Both Mean of 20 sites 
Karvonen 2002b W15 ‡ 253 Finland White Population sample 51±6 100 Low  CCA/BIF/ICA Far Both Mean of 10 sites 
Asakimori 2003 W16 ‡ 162 Japan E.Asian Hemodialysis patients 55±11 52 High  CCA Far Both Maximum 
Beilby 2003 W17 1079 Australia White Population sample 53±13 50 Low  CCA Far Both Mean of 3 each side 
Li 2003 W18 92 China E.Asian Hypertensive patients 64±11 55 High  CCA * * * 
Xiang 2003a W19 253 China E.Asian NIDDM patients * * High  CCA/BIF/ICA Far Both Mean of 3 each side 
Xiang 2003b W19 106 China E.Asian Healthy controls * * Low  CCA/BIF/ICA Far Both Mean of 3 each side 
Elosua 2004 W20 2723 US White Population sample 59±10 48 Low  CCA Both Both Mean of max each side 
Fernandez 2004 W21 225 Spain White CHD patients 61±8 85 High * CCA Far Both Mean of 3 each side 
Kahraman 2004 W22 118 Turkey White Renal transplant recipients 40±8 68 High * CCA * Both Mean of left and right 
Bednarska 2005 W23 127 Poland White Alcoholics 49±6 100 High  CCA Far Both Mean of 3 each side 
Bleil 2006 W24 182 US White Hypertensive patients 56±9 100 High  CCA/BIF/ICA Both Both Mean of all sites 
Brenner 2006 W25 ‡ 470 France White Ischemic stroke patients range 18-85 * High * CCA Far Both Mean of right and left 
Debette 2006 W26 5764 France White Population sample 74±5 40 Low  CCA Far Both Mean of right and left 
Junyent 2006 W27 ‡ 163 Spain White Familial hypercholesterolemia patients 47±* * High  CCA Far Both Mean of right and left 
Volcik 2006a W28 3187 US Black Population sample range 45-64† * Low  CCA/BIF/ICA * Both Mean of 6 sites 
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Study (first author & 
publication year) 
No. of 
subjects Country 
Ethnicity of 
subjects Type of subjects Mean age ± SD % male 
Vascular 
risk status HWE Carotid segment 
Near/far 
carotid wall 
Right/left 
carotid Mean/max 
Volcik 2006b W28 9304 US White Population sample range 45-64† * Low  CCA/BIF/ICA * Both Mean of 6 sites 
Altamura 2007a W29 ‡ 68 Italy White Alzheimer disease patients 75±8 31 High * CCA * Both Mean of right and left 
Altamura 2007b W29 ‡ 33 Italy White Vascular dementia patients 77±8 51 High * CCA * Both Mean of right and left 
Wohlin 2007 W30 437 Sweden White Population sample all 75 100 Low  CCA Far Both Mean of 3 each side 
 
            
ACE 
            
Castellano 1995 W31 187 Italy White Population sample 58±3 52 Low  CCA/BIF/ICA  Both Mean of all sites 
Dessi 1995 W32 240 Italy White Outpatients without vascular risk factors 53±7 57 Low  CCA/BIF/ICA Both Both Mean 
Markus 1994 W33 101 UK White Ischemic CVD patients 65±9 68 High  CCA Far * Maximum 
Kauma 1996 W34 515 Finland White Hypertensive patients 51±6 49 High  CCA Far Both Mean of max at each site 
Puija 1996 W35 132 Italy White NIDDM patients 50±10 100 High  CCA Far Both Mean of 6 sites 
Kogawa 1997a W3 356 Japan E.Asian NIDDM patients 60±11 58 High  CCA/BIF * * Mean of 3 sites 
Kogawa 1997b W3 235 Japan E.Asian Non-diabetic subjects 51±11 37 Low  CCA/BIF * * Mean of 3 sites 
Watanabe 1997 W36 § 169 Japan E.Asian Healthy volunteers 59±6 51 Low  CCA/BIF/ICA Both Both Mean 
Arnett 1998 W37 495 US White Population sample 59±6 42 Low  CCA/BIF/ICA Far Both Mean of 6 sites 
Frost 1998 W38 148 Germany White IDDM patients 30±7 38 High  CCA Far Both Maximum 
Girerd 1998 W39 340 France White Patients with vascular risk factors/disease 49±12 53 High  CCA Far Right One measurement 
Sass 1998 W40 150 France White Population sample 41±4 52 Low  CCA Far Both Mean of all 
Ferrieres 1999 W41 355 France White Population sample 54±7 100 Low  CCA Far Both Mean of 12 sites 
Huang 1999 W42 219 Finland White Population sample 54±3 100 Low  CCA Far Both Maximum 
Hung 1999 W43 1106 Australia White Population sample 53±12 50 Low  CCA Far Both Mean of 6 sites 
Nergizoglu 1999 W44 51 Turkey White Hemodialysis patients 36±9 69 High  CCA Far Both Mean of 6 sites 
Pit'ha 1999 W45 47 Czech Republic White Hypertensive patients  62±3 100 High  CCA Far Both Mean of 10 sites 
Jeng 2000 W46 175 China E.Asian Hypertensive patients 57±10 52 High X CCA Far Both Mean of right and left 
Pontremoli 2000 W47‡ 215 Italy White Hypertensive patients 48±9 62 High  CCA Far Both Mean of 3 sites 
Taute 2000 W48 98 Germany White PAD patients 61±9 79 High  CCA Far Both Maximum 
Mannami 2001 W49 3657 Japan E.Asian Population sample 60±12 46 Low  CCA Both Both Mean of 4 sites 
Markus 2001a W50 ‡ 199 UK White Population sample 60±8 100 Low  CCA Far Both Mean 
Markus 2001b W50 ‡ 88 UK Black Population sample 64±8         
Tabara 2001 W13 205 Japan E.Asian Healthy population sample 70±9 32 Low  CCA Far Right Mean 
Balkestein 2002 W51 380 Belgium White Population sample 40±16 50 Low  CCA Far Right Mean of 3 sites 
Diamantopoulos 2002 W52 184 Greece White NIDDM patients 62±8 41 High  CCA Far Both Max of mean from each side 
Kawamoto 2002 W53 § 184 Japan E.Asian In-patients being evaluated for possible 
atherosclerosis 
67±14 47 High  CCA Far Both Mean of right and left 
Piao 2002 W54 § 262 Japan E.Asian NIDDM patients 58±10 66 High * CCA/BIF/ICA * Both Mean of 6 sites 
Czarnecka 2004a W55 127 Poland White Population sample – parents 51±5 40 Low  CCA Both Both * 
Czarnecka 2004b W55 157 Poland White Population sample – offspring 24±5 50 Low  CCA Both Both * 
Li 2004 W56 102 China E.Asian Hypertensive patients 54±9 * High X CCA Both Both Mean of 12 sites 
Pall 2004a W57 120 Hungary White Hypertensive students 16±1 53 High  CCA * * Mean of 3 sites 
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Study (first author & 
publication year) 
No. of 
subjects Country 
Ethnicity of 
subjects Type of subjects Mean age ± SD % male 
Vascular 
risk status HWE Carotid segment 
Near/far 
carotid wall 
Right/left 
carotid Mean/max 
Pall 2004b W57 58 Hungary White Non-hypertensive students * * Low  CCA * * Mean of 3 sites 
Bednarska 2005 W23 130 Poland White Alcoholics 48±6 100 High  CCA Far Both Mean of each side 
Sleegers 2005 W58 6488 Netherlands White Population sample 69±9 41 Low  CCA Both Both * 
Varda 2005a W59 ‡ 56 Slovenia White Offspring of CVD patients 18±6 52 High  CCA/ICA * Both Mean of 4 sites 
Varda 2005b W59 ‡ 48 Slovenia White Subjects without parental history of CVD 18±6 52 Low  CCA/ICA * Both Mean of 4 sites 
Bilici 2006 W60 64 Turkey White Memory impaired patients 57±13 83 High  CCA Far Both Mean of right and left 
Brenner 2006 W25 ‡ 470 France White Ischemic stroke patients range 18-85 * High * CCA Far Both Mean of right and left 
Burdon 2006 W61 ‡ 737 US White NIDDM patients & their siblings 61±10 43 High  CCA Both Both Mean of 20 sites 
Islam 2006 W62 224 Finland White Population sample 34±2 54 Low  CCA Far Left Mean of 4 sites 
Yamasaki 2006 W63 ‡ 690 Japan E.Asian NIDDM patients 63±7 52 High * CCA/BIF/ICA * Both Mean of max 
Bartoli 2007 W64 § 53 Italy White Systemic sclerosis patients 60±11 11 High  CCA Far Both Mean of right and left 
Tanriverdi 2007 W65 88 Japan E.Asian Coronary angiography patients 55±11 55 High X CCA * Both Mean of 8 sites 
 
            
MTHFR 
            
Arai 1997 W66 222 Japan E.Asian NIDDM patients 60±8 73 High  BIF Both Both Maximum 
Demuth 1998 W67 ‡ 144 France White Patients with vascular risk factors/disease 48±13 46 High  CCA Far Right * 
Mazza 1999 W68 95 Italy White NIDDM patients 53±10 35 High  CCA Far Both Mean of 6 sites 
McQuillan 1999 W69 ‡ 1111 Australia White Population sample 53±13 50 Low  CCA Far Both Mean of 6 sites 
Kawamoto 2001 W70 ‡ 136 Japan E.Asian Patients with vascular risk factors 74±12 45 High  CCA Far Both Mean 
Lim 2001 W71 151 Taiwan E.Asian End stage renal disease patients 55±14 42 High  CCA Both * Mean 
Markus 2001a W50 ‡ 195 UK White Population sample 60±8 100 Low  CCA Far Both Mean 
Markus 2001b W50 ‡ 84 UK Black Population sample 64±8         
Pallaud 2001 W72 § 121 France White Population sample 43±5 64 Low  CCA Far Both Mean 
Passaro 2001 W73 120 Italy White Healthy post-menopausal women 62±4 0 Low  CCA Both Both Mean of max 
Ravera 2001 W74 206 Italy White Hypertensive patients 48±9 * High  CCA Far Both Mean of 3 sites 
Scaglione 2002 W75 124 Italy White NIDDM patients 65±8 76 High  CCA Far Both Mean of 6 sites 
de Maat 2003 W76 ‡ 691 Denmark White Population sample All 60 47 Low  CCA/BIF/ICA Both Right Mean of 3 sites 
Inamoto 2003 W77 3247 Japan E.Asian Population sample 59±13 48 Low  CCA Both Both Mean 
Kelemen 2004a W78 ‡  260 Canada White Population sample 49±* 49 Low  CCA/BIF/ICA Both Both Mean of max 
Kelemen 2004b W78 ‡ 275 Canada E.Asian Population sample 47±* 53 Low  CCA/BIF/ICA Both Both Mean of max 
Kelemen 2004c W78 ‡ 283 Canada S.Asian Population sample 48±* 54 Low  CCA/BIF/ICA Both Both Mean of max 
Durga 2005 W79 815 Netherlands White Patients with high homocysteine 60±6 72 High  CCA Both Both Mean of max 
McDonald 2005 W80 ‡ 201 Australia White Population sample 37±* 44 Low X CCA Both * Mean of 6 sites 
Linnebank 2006 W81 714 Germany White Vascular event patients 64±9 49 High  CCA Far * Mean 
Yamasaki 2006 W63 ‡ 690 Japan E.Asian NIDDM patients 63±7 52 High * CCA/BIF/ICA * Both Mean of max 
Fernandez 2007 W82 § 61 Spain White Patients with coronary disease 68±7 82 High * CCA Far Both Mean of 6 sites 
Liu 2007 W83 541 Taiwan E.Asian Healthy volunteers 53±15 50 Low  CCA Far Either Mean of 4 sites 
 
            
NOS3 
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Study (first author & 
publication year) 
No. of 
subjects Country 
Ethnicity of 
subjects Type of subjects Mean age ± SD % male 
Vascular 
risk status HWE Carotid segment 
Near/far 
carotid wall 
Right/left 
carotid Mean/max 
Lembo 2001 W84 ‡ 375 Italy White Hypertensive patients 54±* 55 High  CCA/BIF/ICA Both Both Maximum 
Karvonen 2002 a W85 505 Finland White Hypertensive patients 51±6 49 High  CCA Far Both Mean of 10 sites 
Karvonen 2002b W85 519 Finland White Population sample 51±7 50 Low  CCA Far Both Mean of 10 sites 
Asakimori 2003 W16 ‡ 163 Japan E.Asian Hemodialysis patients 55±11 52 High  CCA Far Both Maximum 
Schmoelzer 2003 W86 § 932 Italy White Population sample 53±6 55 Low  CCA/BIF/ICA Both Both Mean of 12 sites 
Paradossi 2004 W87 118 Italy White Population sample 30±5 39 Low  CCA * Both Mean of max 
Czarnecka 2005a W88 127 Poland White Population sample – parents 51±5 40 Low  CCA Both Both * 
Czarnecka 2005b W88 167 Poland White Population sample – offspring 24±5 50 Low  CCA Both Both * 
Spoto 2005 W89 131 Italy White Hemodialysis patients 61±13 60 High  CCA/BIF/ICA Far Both Mean of 12 sites 
Wolff 2005 W90 2448 Germany White Population sample 62±10 51 Low  CCA Far Both Mean of 20 sites 
Brenner 2006 W25 ‡ 470 France White Ischemic stroke patients range 18-85 * High * CCA Far Both Mean of right and left 
Burdon 2006 W61 ‡ 737 US White NIDDM patients & their siblings 61±10 43 High  CCA Both Both Mean of 20 sites 
Lekakis 2006 W91§ 122 Greece White Coronary angiography patients 61±10 84 High * CCA/BIF/ICA Far Both Mean of max of 6 sites 
Bhuiyan 2007 W92 § 661 US White Population sample 37±4 40 Low  CCA Far Both Mean of max of 6 sites 
 
            
ADD1 
            
Castellano 1997 W93 173 Italy White Population sample 57±5 50 Low  CCA Far Both Mean 
Balkestein 2002 W51 380 Belgium White Population sample 40±16 49 Low  CCA Far Right Mean of 3 sites 
Sarzani 2006 W94 § 420 Italy White Medical student volunteers 23±2 52 Low X CCA/BIF Both Both Mean of max of 8 sites 
Yazdanpanah 2006 W95 5083 Netherlands White Population sample 69±9 40 Low  CCA Both Both Mean of 6 sites 
 
 
Grey shaded studies are those which were not included in our analyses because complete data were unavailable, either in publication or on request from 
authors. 
* information not available from publication, †data only available for whole study so estimated to be equal for each sub-study, ‡studies with all result data 
unavailable from the publication, §studies with result data only relating to a particular genetic model available in the publication. 
APOE: apolipoprotein E; ACE: angiotensin I converting enzyme ; MTHFR: 5,10-methylenetetrahydrofolate reductase; NOS3: nitric oxide synthase 3; ADD1: 
adducin 1 (alpha); HWE: Hardy Weinberg equilibrium; CCA: common carotid artery; BIF: bifurcation; ICA: internal carotid artery; NIDDM: non-insulin-
dependent diabetes mellitus; CHD: coronary heart disease; CVD: cerebrovascular disease; IDDM: insulin-dependent diabetes mellitus; PAD: peripheral 
artery disease. 
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Supplemental table 2. Sample size required to detect a CIMT difference ranging from 
10 to 100 m per genotype in a co-dominant model for a genetic polymorphism with  
minor allele frequency of 0.05, 0.1 or 0.2, at (a) 80% power, 2-sided p< 0.05, and (b) 
90% power, 2-sided p<0.01*  
 
(a) 80% power, p<0.05 
 
 Minor allele frequency 
CIMT difference (m) 0.05 0.1 0.2 
10 21147 11159 6275 
25 3380 1782 1001 
50 842 443 247 
100 208 108 59 
 
(b) 90% power, p<0.01 
 
 Minor allele frequency 
CIMT difference (m) 0.05 0.1 0.2 
10 40089 21154 11896 
25 6408 3378 1897 
50 1596 839 469 
100 393 204 111 
 
*sample size calculations performed with Quanto version 1.2 (available at http://hydra.usc.edu/gxe/) 
 
Note that required sample size: 
• approximately doubles with a change from 80 % power, p<0.05 to 90% power, p<0.01;  
• approximately halves for each doubling of minor allele frequency within the range assessed; 
• falls by about 100-fold for a 10-fold increase in detectable CIMT difference per genotype from 10 to 
100 m. 
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Supplemental figures 
 
Supplemental Figure 1 
 
 
-100 0 100 200 300 400
Study Mean CIMT difference per genotype group, E4 v E3 & E3 v E2, (95% CI)
Terry 1996 67 (20 to 114)
Cattin 1997 47 (9 to 86)
Kogawa 1997a 52 (-52 to 156)
Kogawa 1997b 8 (-34 to 50)
Sass 1998 -4 (-16 to 8)
Zhang 1998 281 (2 to 560)
Guz 2000 60 (7 to 114)
Hanon 2000 7 (-16 to 30)
Horejsi 2000 59 (-27 to 144)
Ilveskoski 2000 32 (-1 to 65)
Slooter 2001 10 (3 to 16)
Tabara 2001 18 (-16 to 52)
Haraki 2002 82 (24 to 141)
Karvonen 2002a 60 (10 to 111)
Karvonen 2002b 50 (7 to 94)
Asakimori 2003 8 (-99 to 115)
Beilby 2003 1 (-12 to 13)
Li 2003 110 (42 to 177)
Xiang 2003a 137 (109 to 165)
Xiang 2003b 62 (17 to 107)
Elosua 2004 5 (-7 to 17)
Fernandez 2004 33 (-17 to 83)
Kahraman 2004 76 (-39 to 190)
Bednarska 2005 -2 (-86 to 81)
Bleil 2006 -16 (-56 to 24)
Debette 2006 5 (-1 to 10)
Junyent 2006 44 (-11 to 99)
Volcik 2006a 12 (6 to 18)
Volcik 2006b 10 (6 to 14)
Altamura 2007a 99 ( 51 to 147)
Altamura 2007b -4 (-32 to 23)
Wohlin 2007 13 (-10 to 36)
Overall 25 (17 to 33)
Olmer 1997 E4 associated with higher CIMT
Vauhkonen 1997a no association
Vauhkonen 1997b E4 associated with higher CIMT
Brenner 2006 no association
Sample size
254
254
349
231
144
52
261
312
112
189
5264
202
95
258
253
162
1079
92
253
106
2723
225
118
127
182
5764
163
3187
9304
68
33
437
322253
66
83
123
470
SUPPLEMENTARY FIGURE 1 
I²=80%
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Supplemental Figure 2 
 
SUPPLEMENTARY FIGURE 2 
-200 -100 0 100 200
Study Mean CIMT difference per D allele in µm (95% CI)
Castellano 1995 (-2 to 55)
Dessi 1995 15 (-43 to 73)
Markus 1995 -149 (-239 to -60)
Kauma 1996 12 (-11 to 35)
Puija 1996 32 (12 to 52)
Kogawa 1997b 5 (-27 to 36)
Kogawa 1997a 94 (25 to 163)
Arnett 1998 5 (-15 to 24)
Frost 1998 4 (-26 to 34)
Girerd 1998 6 (-11 to 22)
Sass 1998 5 (-5 to 14)
Ferrieres 1999 8 (-9 to 24)
Huang 1999 -22 (-62 to 17)
Hung 1999 0 (-12 to 12)
Nergizoglu 1999 45 (17 to 73)
Pit'ha 1999 13 (-48 to 74)
Jeng 2000 60 (-1 to 121)
Taute 2000 12 (-64 to 88)
Mannami 2001 0 (-14 to 14)
Tabara 2001 10 (-16 to 36)
Balkestein 2002 11 (-12 to 35)
Diamantopoulos 2002 18 (-24 to 61)
Czarnecka 2004a 95 (-29 to 219)
Czarnecka 2004b 41 (-35 to 116)
Li 2004 104 (70 to 137)
Pall 2004b -15 (-49 to 19)
Pall 2004a 7 (-19 to 33)
Bednarska 2005 -6 (-56 to 44)
Sleegers 2005 5 (-1 to  10)
Varda 2005b -10 (-36 to 17)
29 ( 3 to 55)
Bilici 2006 -11 (-118 to 96)
Islam 2006 -16(-3 to -1)
Tanriverdi 2007 70 (54 to 86)
 14 ( 5 to 22)
Varda 2005a
Pontremoli 2000 No association
Watanabe 1997 No association
Markus 2001 No association
Kawamoto 2002 No association
Brenner 2006 Trend towards higher CIMT with DD
Not reported
Burdon 2006 No association
Yamasaki 2006 DD associated with higher CIMT
Bartoli 2007 D allele associated with higher CIMT
Piao 2002
Sample size
187
240
101
515
132
235
356
495
148
340
150
355
219
1106
51
47
175
98
3657
205
380
184
127
157
102
58
120
130
6488
48
64
224
88
	

56
215
169
287
184
470
737
690
53
262
I²=78%
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Supplemental Figure 3 
 
-200 -100 0 100 200 300 400
Study Mean CIMT difference between TT and CT/CC genotypes in µm (95% CI)
Arai 1997 250 (74 to 426)
Lim 2001 120 (71 to 169)
Durga 2005 10 (-21 to 41)
Linnebank 2006 -20 (-71 to 31)
Mazza 1999 25 (-68 to 118)
Ravera 2001 120 (17 to 223)
Scaglione 2002 -10 (-115 to 95)
Inamoto 2003 0 (-3 to 3)
Liu 2007 20 (-46 to 86)
Kelemen 200b -5 (-74 to 65)
Kelemen 200c 95 (-16 to 207)
DeMaat 2003 -48 (-78 to-18)
Passaro 2001 210 ( 124 to 296)
Keleman 200a 47 (-42 to 137)
McDonald 2005 -74 (-119 to -29)
Overall 29 (0 to 58)
Markus 2001 No association
Yamasaki 2006 TT associated with higher CIMT
Fernandez 2007 TT associated with higher CIMT
McQuillan 1999 No association
Kawamoto 2001 T allele associated with higher CIMT
Demuth 1998 TT associated with lower CIMT
Pallaud 2001 T allele associated with higher CIMT in men only
Sample size
222
151
815
714
95
206
124
3247
541
275
283
691
120
260
201
7855
279
690
61
1111
136
144
121
I²=83%
SUPPLMENTARY FIGURE 3 
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Supplemental figure legends 
 
Supplemental Figure 1. Meta-analysis of APOE (2/3/4). The data are analysed according to a co-
dominant genetic model.  The size of the squares represents the weight of the study in the random effects 
model.  The diamond represents the random effects pooled mean difference and its width represents the 
95% confidence interval.  No data were available for the four studies below the pooled estimate, but we 
show qualitative statements of the results from these studies. Heterogeneity between studies is 
represented by the I2 value shown. 
Supplemental Figure 2. Meta-analysis of ACE (I/D). The data are analysed according to a co-dominant 
genetic model.  The size of the squares represents the weight of the study in the random effects model.  
The diamond represents the random effects pooled mean difference.  No data were available for the nine 
studies below the pooled estimate, but we show qualitative statements of the results from these studies. 
Heterogeneity between studies is represented by the I2 value shown. 
Supplemental Figure 3. Meta-analysis of MTHFR (677 C/T). The data are analysed according to a 
recessive genetic model.  The size of the squares represents the weight of the study in the random effects 
model.  The diamond represents the random effects pooled mean difference.  No data were available for 
the four studies below the pooled estimate, but we show qualitative statements of the results from these 
studies. Heterogeneity between studies is represented by the I2 value shown. 
 
 at UNIVERSITY EDINBURGH on June 11, 2013circgenetics.ahajournals.orgDownloaded from 
Supplemental references 
W1. Terry JG, Howard G, Mercuri M, Bond MG, Crouse JR. Apolipoprotein E polymorphism is 
associated with segment-specific extracranial carotid artery intima-media thickening. Stroke 1996; 
27:1755-1759. 
W2. Cattin L, Fisicaro M, Tonizzo M, Valenti M, Danek GM, Fonda M, Da Col PG, Casagrande S, 
Pincetti E, Bovenzi M, Baralle F. Polymorphism of the apolipoprotein E gene and early carotid 
atherosclerosis defined by ultrasonography in asymptomatic adults. Arterioscler Thromb Vasc Biol 1997; 
17:91-94. 
W3. Kogawa K, Nishizawa Y, Hosoi M, Kawagishi T, Maekawa K, Shoji T, Okuno Y, Morii H. Effect of 
polymorphism of apolipoprotein E and angiotensin-converting enzyme genes on arterial wall thickness. 
Diabetes 1997; 46:682-687.  
W4. Olmer M, Renucci JE, Planells R, Bouchouareb D, Purgus R. Preliminary evidence for a role of 
apolipoprotein E alleles in identifying haemodialysis patients at high vascular risk. Nephrol Dial Transplant 
1997; 12:691-693. 
W5. Vauhkonen I, Niskanen L, Ryynanen M, Voutilainen R, Partanen J, Toyry J, Mercuri M, Rauramaa 
R, Uusitupa M. Divergent association of apolipoprotein E polymorphism with vascular disease in patients 
with NIDDM and control subjects. Diabet Med 1997; 14:748-756. 
W6. Sass C, Zannad F, Herbeth B, Salah D, Chapet O, Siest G, Visvikis S. Apolipoprotein E4, 
lipoprotein lipase C447 and angiotensin-I converting enzyme deletion alleles were not associated with 
increased wall thickness of carotid and femoral arteries in healthy subjects from the Stanislas cohort. 
Atherosclerosis 1998; 140:89-95. 
W7. Zhang Y, You K, Zhang L, Jiang Y. Effect of apolipoprotein E polymorphism on serum lipids, 
coronary heart disease, and carotid artery atherosclerosis. Chin J Cardiol 1998; 26:443-447. 
W8. Guz G, Nurhan OF, Sezer S, Isiklar I, Arat Z, Turan M, Haberal M. Effect of apolipoprotein E 
polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. Am J Kidney Dis 
2000; 36:826-836. 
 at UNIVERSITY EDINBURGH on June 11, 2013circgenetics.ahajournals.orgDownloaded from 
W9. Hanon O, Girerd X, Luong V, Jeunemaitre X, Laurent S, Safar ME. Association between the 
apolipoprotein E polymorphism and arterial wall thickness in asymptomatic adults. J Hypertens 2000; 
18:431-436. 
W10. Horejsi B, Spacil J, Ceska R, Vrablik M, Haas T, Horinek A. The independent correlation of the 
impact of lipoprotein(a) levels and apolipoprotein E polymorphism on carotid artery intima thickness. Int 
Angiol 2000; 19:331-336. 
W11. Ilveskoski E, Loimaala A, Mercuri MF, Lehtimaki T, Pasanen M, Nenonen A, Oja P, Bond, MG, 
Koivula T, Karhunen PJ, Vuori I. Apolipoprotein E polymorphism and carotid artery intima-media thickness 
in a random sample of middle-aged men. Atherosclerosis 2000; 153:147-153. 
W12. Slooter AJC, Bots ML, Havekes LM, Iglesias DS, Cruts M, Grobbee DE, Hofman A, van 
Broeckhoven C, Witteman JCM, van Duijn CM. Apolipoprotein E and carotid artery atherosclerosis: The 
Rotterdam study. Stroke 2001; 32:1947-1952. 
W13. Tabara Y, Kohara K, Nakura J, Miki T. Risk factor-gene interaction in carotid atherosclerosis: 
effect of gene polymorphisms of renin-angiotensin system. J Hum Genet 2001; 46:278-284.  
W14. Haraki T, Takegoshi T, Kitoh C, Wakasugi T, Saga T, Hirai JI, Aoyama T, Inazu A, Mabuchi H. 
Carotid artery intima-media thickness and brachial artery flow-mediated vasodilation in asymptomatic 
Japanese male subjects amongst apolipoprotein E phenotypes. J Intern Med 2002; 252:114-120. 
W15. Karvonen J, Kauma H, Kervinen K, Ukkola O, Rantala M, Paivansalo M, Savolainen MJ, 
Kesaniemi YA. Apolipoprotein E polymorphism affects carotid artery atherosclerosis in smoking 
hypertensive men. J Hypertens 2002; 20:2371-2378. 
W16. Asakimori Y, Yorioka N, Tanaka J, Kohno N. Effect of polymorphism of the endothelial nitric oxide 
synthase and apolipoprotein E genes on carotid atherosclerosis in hemodialysis patients. Am J Kidney Dis 
2003; 41:822-832. 
W17. Beilby JP, Hunt CCJ, Palmer LJ, Chapman CML, Burley JP, McQuillan BM, Thompson PL, Hung 
J. Apolipoprotein E gene polymorphisms are associated with carotid plaque formation but not with intima-
media wall thickening: Results from the Perth Carotid Ultrasound Disease Assessment Study (CUDAS). 
Stroke 2003; 34:869-874. 
 at UNIVERSITY EDINBURGH on June 11, 2013circgenetics.ahajournals.orgDownloaded from 
W18. Li X, Du Y, Du Y, Huang X. Association of apolipoprotein E gene polymorphism with essential 
hypertension and its complications. Clin Exp Med 2003; 2:175-179. 
W19. Xiang GD, Hu TH, Wang YL. Apolipoprotein E genotypes and carotid artery atherosclerosis in 
type 2 diabetes mellitus. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2003; 20:66-68. 
W20. Elosua R, Ordovas JM, Cupples LA, Fox CS, Polak JF, Wolf PA, D’Agostino RA, O’Donnell CJ. 
Association of APOE genotype with carotid atherosclerosis in men and women: the Framingham Heart 
Study. J Lipid Res 2004; 45:1868-1875. 
W21. Fernandez-Miranda C, Aranda JL, Martin MA, Arenas J, Nunez V, Gomez DLC. Apolipoprotein E 
polymorphism and carotid atherosclerosis in patients with coronary disease. Int J Cardiol 2004; 94:209-
212. 
W22. Kahraman S, Kiykim AA, Altun B, Genctoy G, Arici M, Gulsun M, Erdem Y, Yasavul U, Turgan C, 
Caglar S. Apolipoprotein E gene polymorphism in renal transplant recipients: effects on lipid metabolism, 
atherosclerosis and allograft function. Clin Transplant 2004; 18:288-294. 
W23. Bednarska-Makaruk M, Rodo M, Markuszewski C, Rozenfeld A, Swiderska M, Habrat B, Wehr H. 
Polymorphisms of apolipoprotein E and angiotensin-converting enzyme genes and carotid atherosclerosis 
in heavy drinkers. Alcohol Alcohol 2005; 40:274-282. 
W24. Bleil ME, Ferrell RE, Sutton-Tyrrell K, Muldoon MF, Manuck SB. Apolipoprotein E polymorphism 
and preclinical carotid artery disease in untreated hypertensive men. Eur J Cardiovasc Prev Rehabil 2006; 
13:98-100. 
W25. Brenner D, Labreuche J, Touboul P-J, Schmidt-Petersen K, Poirer O, Perret C, Schönfelder J, 
Combadière C, Lathrop M, Cambien F, Brand-Herrmann S-M, Amarenco P. Cytokine polymorphisms 
associated with carotid intima-media thickness in stroke patients. Stroke 2006; 37:1691-1696. 
W26. Debette S, Lambert J-C, Gariépy J, Fievet N, Tzurio C, Dartigues J-F, Ritchie K, Dupuy A-M, 
Alpérovitch A, Ducimetière P, Amouyel P, Zureik M. New insight into the association of apolipoprotein E 
genetic variants with carotid plaques and intima-media thickness. Stroke 2006; 37:2917-2923. 
W27. Junyent M, Cofán M, Núñez I, Gilabert R, Zambón D, Ros E. Influence of HDL cholesterol on 
preclinical carotid atherosclerosis in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006; 
26:1107-1113. 
 at UNIVERSITY EDINBURGH on June 11, 2013circgenetics.ahajournals.orgDownloaded from 
W28. Volcik KA, Barkley RA, Hutchinson RG, Mosley TH, Heiss G, Sharrett AR, Ballantyne CM, 
Boerwinkle E. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and 
carotid wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J 
Epid 2006; 164:342-348. 
W29. Altamura C, Squitti R, Pasqualetti P, Tibuzzi F, Silvestrini M, Ventriglia MC, Cassetta E, Rossini 
PM, Vernieri F. What is the relationship among atherosclerosis markers, apolipoprotein E polymorphism 
and dementia? Eur J Neurol 2007; 14:679-682. 
W30. Wohlin M, Sundström J, Lannfelt L, Axelsson T, Syvänen AC, Andrén B, Basu S, Lind L. 
Apolipoprotein E epsilon4 genotype is independently associated with increased intima-media thickness in 
a recessive pattern. Lipids 2007; 42:451-456.  
W31. Castellano M, Muiesan ML, Rizzoni D, Beschi M, Pasini G, Cinelli A, Salvetti M, Porteri E, Bettoni 
G, Kruetz R, Lindpaintner K, Rosei EA. Angiotensin-converting enzyme I/D polymorphism and arterial wall 
thickness in a general population: The Vobarno Study. Circulation 1995; 91:2721-2724. 
W32. Dessi-Fulgheri P, Catalini R, Sarzani R, Sturbini S, Siragusa N, Guazzarotti F, Offidani, 
Tamburrini P, Zingaretti O, Rappelli. Angiotensin converting enzyme gene polymorphism and carotid 
atherosclerosis in a low-risk population. J Hypertens 1995; 13:1593-1596. 
W33. Markus HS, Barley J, Lunt R, Bland JM, Jeffery S, Carter ND, Brown MN. Angiotensin-converting 
enzyme gene deletion polymorphism: A new risk factor for lacunar stroke but not carotid atheroma. Stroke 
1995; 26:1329-1333. 
W34. Kauma H, Paivansalo M, Savolainen MJ, Rantala AO, Kiema T-R, Lilja M, Runanen A, Kesaniemi 
YA.. Association between angiotensin converting enzyme gene polymorphism and carotid atherosclerosis. 
J Hypertens 1996; 14:1183-1187. 
W35. Pujia A, Motti C, Irace C, Cortese C, Biagiotti L, Mattioli PL, Federici G, Gnasso A. Deletion 
polymorphism in angiotensin converting enzyme gene associated with carotid wall thickening in a healthy 
male population. Coron Artery Dis 1996; 7:51-55. 
W36. Watanabe Y, Ishigami T, Kawano Y, Umahara T, Nakamori A, Mizushima S, Hibi K, Kobayashi I, 
Tamura K, Ochiai H, Umemura S, Ishii M. Angiotensin-converting enzyme gene I/D polymorphism and 
carotid plaques in Japanese. Hypertension 1997; 30:569. 
 at UNIVERSITY EDINBURGH on June 11, 2013circgenetics.ahajournals.orgDownloaded from 
W37. Arnett DK, Borecki IB, Ludwig EH, Pankow JS, Myers R, Evans G, Folsom AR, Heiss G, Higgins 
M. Angiotensinogen and angiotensin converting enzyme genotypes and carotid atherosclerosis: The 
atherosclerosis risk in communities and the NHLBI family heart studies. Atherosclerosis 1998; 138:111-
116.
W38. Frost D, Pfohl M, Clemens P, Haring H-U, Beischer W. Evaluation of the insertion/deletion ACE 
gene polymorphism as a risk factor for carotid artery intima-media thickening and hypertension in young 
type 1 diabetic patients. Diabetes Care 1998; 21:836-840. 
W39. Girerd X, Hanon O, Mourad JJ, Boutouyrie P, Laurent S, Jeunemaitre X. Lack of association 
between renin-angiotensin system, gene polymorphisms, and wall thickness of the radial and carotid 
arteries. Hypertension 1998; 32:579-583. 
W40. Sass C, Zannad F, Herbeth B, Salah D, Chapet O, Siest G, Visvikis S. Apolipoprotein E4, 
lipoprotein lipase C447 and angiotensin-I converting enzyme deletion alleles were not associated with 
increased wall thickness of carotid and femoral arteries in healthy subjects from the Stanislas cohort. 
Atherosclerosis 1998; 140:89-95. 
W41. Ferrieres J, Elias A, Ruidavets J-B, Cantet C, Bongard V, Fauvel J, Boccalon H. Carotid intima-
media thickness and coronary heart disease risk factors in a low-risk population. J Hypertens 1999; 
17:743-748. 
W42. Huang X-H, Loimaala A, Nenonen A, Mercuri M, Vuori I, Pasanen M, Oja P, Bond G, Koivula T, 
Hiltunen TP, Nikkari T, Lehtimaki T. Relationship of angiotensin-converting enzyme gene polymorphism to 
carotid wall thickness in middle-aged men. J Mol Med 1999; 77:853-858. 
W43. Hung J, McQuillan BM, Nidorf M, Thompson PL, Beilby JP. Angiotensin-converting enzyme gene 
polymorphism and carotid wall thickening in a community population. Arterioscler Thromb Vasc Biol 1999; 
19:1969-1974. 
W44. Nergizoglu G, Keven K, Gurses MA, Aras O, Erturk S, Duman N, Ates K, Akar H, Akar N, Karatan 
O, Erbay B, Ertug AE. Carotid intima-media thickness and ACE-gene polymorphism in hemodialysis 
patients. J Nephrol 1999; 12:261-265. 
W45. Pit'ha J, Krajickova D, Cifkova R, Hubacek J, Petrzilkova Z, Hejl Z, Stavek P, Skibova J, Poledne 
R. Intima-media thickness of carotid arteries in borderline hypertensives. J Neuroimaging 1999; 9:19-22. 
 at UNIVERSITY EDINBURGH on June 11, 2013circgenetics.ahajournals.orgDownloaded from 
W46. Jeng JR. Carotid thickening, cardiac hypertrophy, and angiotensin converting enzyme gene 
polymorphism in patients with hypertension. Am J Hypertens 2000; 13:111-119. 
W47. Pontremoli R, Ravera M, Viazzi F, Nicolella C, Berruti V, Leoncini G, Giacopelli F, Bezante GP, 
Sacchi G, Ravazzolo R, Deferrari G. Genetic polymorphism of the renin-angiotensin system and organ 
damage in essential hypertension. Kidney Int 2000; 57:561-569. 
W48. Taute B-M, Seifert H, Taute R, Glaser C, Podhaisky H. Angiotensin-converting enzyme gene 
insertion/deletion polymorphism and carotid artery wall thickness in patients with peripheral arterial 
occlusive disease. Int Angiol 2000; 19:337-344. 
W49. Mannami T, Katsuya T, Baba S, Inamoto N, Ishikawa K, Higaki J, Ogihara T, Ogata J. Low 
potentiality of angiotensin-converting enzyme gene insertion/deletion polymorphism as a useful predictive 
marker for carotid atherogenesis in a large general population of a Japanese City: The Suita study. Stroke 
2001; 32:1250. 
W50. Markus H, Kapozsta Z, Ditrich R, Wolfe C, Ali N, Powell J, Mendell M, Cullinane M. Increased 
common carotid intima-media thickness in UK African Caribbeans and its relation to chronic inflammation 
and vascular candidate gene polymorphisms. Stroke 2001; 32:2465-2471. 
W51. Balkestein EJ, Ji GW, Struijker-Boudier HAJ, Barlassina C, Bianchi G, Birkenhager WH, Brand E, 
Den Hond E, Fagard R, Herrmann S-M, Van Bortel LM, Staessen JA. Carotid and femoral intima-media 
thickness in relation to three candidate genes in a Caucasian population. J Hypertens 2002; 20:1551-
1561. 
W52. Diamantopoulos EJ, Andreadis E, Kakou M, Vlachonikolis I, Vassilopoulos C, Giannakopoulos N, 
Tarassi K, Papasteriades C, Nicolaides A, Raptis S. Atherosclerosis of carotid arteries and the ACE 
insertion/deletion polymorphism in subjects with diabetes mellitus type 2. Int Angiol 2002; 21:63-69. 
W53. Kawamoto R, Kohara K, Tabara Y, Miki T. An interaction between systolic blood pressure and 
angiotensin-converting enzyme gene polymorphism on carotid atherosclerosis. Hypertens Res 2002; 
25:875-880. 
W54. Piao L, Tanaka Y, Nomiyama T, Nakajima K, Ogihara T, Miwa S, Urabe T, Watada H, Kawamori 
R. Combined genotypes of ACE and NADPH oxidase p22phox associated with somatic mutation of 
 at UNIVERSITY EDINBURGH on June 11, 2013circgenetics.ahajournals.orgDownloaded from 
mtDNA and carotid intima-media thickness in Japanese patients with type 2 diabetes mellitus. Curr Ther 
Res Clin Exp 2002; 63:842-852. 
W55. Czarnecka D, Kawecka-Jaszcz K, Stolarz K, Olszanecka A, Kiec-Wilk B, Dembinska-Kiec A, 
Narkiewicz K. Genetic factors in hypertension. Angiotensin-converting enzyme polymorphism. Kardiol Pol 
2004; 61:1-10. 
W56. Li S-J, Sun N-L, Zhou S-M. Carotid remodeling of hypertensive subjects and polymorphism of the 
angiotensin-converting enzyme gene. Chin Med J 2004; 117:49-53. 
W57. Pall D, Settakis G, Katona E, Zatik J, Kollar J, Limburg M, Fulesdi B. Angiotensin-converting 
enzyme gene polymorphism, carotid intima-media thickness, and left ventricular mass index in adolescent 
hypertension. J Clin Ultrasound 2004; 32:129-135. 
W58. Sleegers K, den Heijer T, van Dijk EJ, Hofman A, Bertoli-Avella AM, Koudstaal PJ, Breteler MMB, 
van Diujn CM. ACE gene is associated with Alzheimer’s disease and atrophy of hippocampus and 
amygdala. Neurobiol Aging 2005; 26:1153-1159. 
W59. Varda NM, Peterlin B, Bradac SU, Gregoric A. Carotid artery intima-media thickness and 
angiotensin-converting enzyme gene polymorphism in the offspring of parents with premature stroke. Acta 
Paediatrica 2005; 94:33-37. 
W60. Bilici A, Ulgen MS, Nazaroglu H, Ozturk O, Ekici F, Akgul C, Alan B. The effect of ACE gene 
polymorphisms on doppler blood flow parameters of carotid and brachial arteries in patients with 
myocardial infarction. Angiology 2006; 57:681-685. 
W61. Burdon KP, Langefeld CD, Wagenknecht LE, Carr JJ, Freedman BI, Herrington D Bowden DW.  
Association analysis of genes in the renin-angiotensin system with subclinical cardiovascular disease in 
families with Type 2 diabetes mellitus: The Diabetes Heart Study.  Diabetic Med 2006; 23:228-234. 
W62.  Islam M, Lehtimaki T, Juonala M, Kahonen M, Hutri-Kahonen N, Kainulainen K, Miettinen H, 
Taittonen L, Kontula K, Viikari JSA, Raitakari OT. Polymorphism of the angiotensin-converting enzyme 
(ACE) and angiotesinogen (AGT) genes and their associations with blood pressure and carotid artery 
intima media thickness among healthy Finnish young adults-the Cardiovascular Risk in Young Finns 
Study. Atherosclerosis 2006; 188:316-322. 
 at UNIVERSITY EDINBURGH on June 11, 2013circgenetics.ahajournals.orgDownloaded from 
W63. Yamasaki Y, Katakami N, Sakamoto K, Kaneto H, Matsuhisa M, Sato H, Hori M, Haneda M, 
Kashwagi A, Tanaka Y, Kawamori R, Kuno S-I. Combination of multiple genetic risk factors is 
synergistically associated with carotid atherosclerosis in Japanese subjects with type 2 diabetes. Diabetes 
Care 2006; 29:2445-2451. 
W64. Bartoli F, Angotti C, Fatini C, Conforti ML, Guiducci S, Blagojevic J, Melchiorre D, Fiori G, 
Generini S, Damjanov N, Rednic S, Pignone A, Castellani S, Abbate R, Matucci CM. Angiotensin-
converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis. Rheumatology 
2007; 46:772-775. 
W65. Tanriverdi H, Evrengul H, Mergen H, Acar C, Seleci D, Kuro O, Tanriverdi S, Kaftan A. Early sign 
of atherosclerosis in slow coronary flow and relationship with angiotensin-converting enzyme I/D 
polymorphism. Heart Vessels 2007; 22:1-8. 
W66. Arai K, Yamasaki Y, Kajimoto Y, Watada H, Umayahara Y, Kodama M, Sakamoto K, Hori M. 
Association of methylenetetrahydrofolate reductase gene polymorphism with carotid arterial wall 
thickening and myocardial infarction risk in NIDDM. Diabetes 1997; 46:2102-2104. 
W67. Demuth K, Moatti N, Hanon O, Benoit MO, Safar M, Girerd X. Opposite effects of plasma 
homocysteine and the methylenetetrahydrofolate reductase C677T mutation on carotid artery geometry in 
asymptomatic adults. Arterioscler Thromb Vasc Biol 1998; 18:1838-1843. 
W68. Mazza A, Motti C, Nulli A, Pastore A, Andreotti F, Ammaturo V, Bianco P, Santoro E, Federici G, 
Cortese C. Serum homocysteine, MTHFR gene polymorphism, and carotid intimal-medial thickness in 
NIDDM subjects. J Thrombosis Thrombolysis 1999; 8:207-212. 
W69. McQuillan BM, Beilby JP, Nidorf M, Thompson PL, Hung J. Hyperhomocysteinemia but not the 
C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall 
thickening: The Perth carotid ultrasound disease assessment study (CUDAS). Circulation 1999; 99:2383-
2388. 
W70. Kawamoto R, Kohara K, Tabara Y, Miki T, Doi T, Tokunaga H, Konishi I. An association of 5,10-
methylenetetrahydrofolate reductase (MTHFR) gene polymorphism and common carotid atherosclerosis. 
J Hum Genet 2001; 46:506-510. 
 at UNIVERSITY EDINBURGH on June 11, 2013circgenetics.ahajournals.orgDownloaded from 
W71. Lim PS, Hung W-R, Wei Y-H. Polymorphism in methylenetetrahydrofolate reductase gene: Its 
impact on plasma homocysteine levels and carotid atherosclerosis in ESRD patients receiving 
hemodialysis. Nephron 2001; 87:249-256. 
W72. Pallaud C, Sass C, Zannad F, Siest G, Visvikis S. APOC3, CETP, fibrinogen and MTHFR are 
genetic determinants of carotid intima-media thickness in supposed healthy men (the Stanislas cohort). 
Clin Genet 2001; 59:316-324. 
W73. Passaro A, Vanini A, Calzoni F, Alberti L, Zamboni PF, Fellin R, Solini A. Plasma homocysteine, 
methylenetetrahydrofolate reductase mutation and carotid damage in elderly healthy women. 
Atherosclerosis 2001; 157:175-180. 
W74. Ravera M, Viazzi F, Berruti V, Leoncini G, Zagami P, Bezante GP, Rosatto N, Ravazzolo R, 
Pontremoli R, Deferrari G. 5,10-methylenetetrahydrofolate reductase polymorphism and early organ 
damage in primary hypertension. Am J Hypertens 2001; 14:371-376. 
W75. Scaglione L, Gambino R, Rolfo E, Lillaz E, Gai M, Cassader M, Pagano G, Cavallo-Perin P. 
Plasma homocysteine, methylenetetrahydrofolate reductase gene polymorphism and carotid intima-media 
thickness in Italian type 2 diabetic patients. Eur J Clin Invest 2002; 32:24-28. 
W76. de Maat MP, Bladbjerg EM, Drivsholm T, Borch-Johnsen K, Moller L, Jespersen J. Inflammation, 
thrombosis and atherosclerosis: results of the Glostrup study. J Thromb Haemost 2003; 1:950-957. 
W77. Inamoto N, Katsuya T, Kokubo Y, Mannami T, Asai T, Baba S, Ogata J, Tomoike H, Ogihara T. 
Association of methylenetetrahydrofolate reductase gene polymorphism with carotid atherosclerosis 
depending on smoking status in a Japanese general population. Stroke 2003; 34:1628-1633. 
W78. Kelemen LE, Anand SS, Hegele RA, Stampfer MJ, Rosner B, Willett WC, Montague PA, Lonn E, 
Vuksan V, Teo KK, Devanesen S, Yusuf S. Associations of plasma homocysteine and the 
methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among 
South Asian, Chinese and European Canadians. Atherosclerosis 2004; 176:361-370. 
W79. Durga J, Bots ML, Schouten EG, Kok FJ, Verhoef P. Low concentrations of folate, not 
hyperhomocysteinemia, are associated with carotid intima-media thickness. Atherosclerosis 2005; 
179:285-292. 
 at UNIVERSITY EDINBURGH on June 11, 2013circgenetics.ahajournals.orgDownloaded from 
W80. McDonald S, Maguire G, Duarte N, Wang XL, Hoy W. Homocysteine, renal disease and 
cardiovascular disease in a remote Australian Aboriginal community. Intern Med J 2005; 35:289-294. 
W81. Linnebank M, Moskau S, Farmand S, Fliessbach K, Kolsch H, Bos M, Grothe C, Becker D, 
Harbrecht U, Pohl C, Wullner U, Klockgether T. Homocysteine and carotid intima-media thickness in a 
German population: Lack of clinical relevance. Stroke 2006; 37:2840-2842. 
W82. Fernández-Miranda C, Yebra M, Aranda J, Gómez P, Martínez J, Núñez V, Gómez de la Cámara 
A. Effect of folic acid treatment on carotid intima-media thickness of patients with coronary disease. Int J 
Cardiol 2007; 118:345-349. 
W83. Liu CS, Chen CH, Chiang HC, Kuo CL, Huang CS, Cheng WL, Wei YH, Chen HW. B-group 
vitamins, MTHFR C677T polymorphism and carotid intima-media thickness in clinically healthy subjects. 
Eur J Clin Nutr 2007; 61:996-1003. 
W84. Lembo G, De Luca N, Battagli C, Iovino G, Aretini A, Musicco M, Frati G, Pompeo F, Vecchione 
C, Trimarco B. A common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk 
factor for carotid atherosclerosis. Stroke 2001; 32:735-740. 
W85. Karvonen J, Kauma H, Kervinen K, Rantala M, Ikaheimo M, Paivansalo M, Savolainen MJ, 
Kesaniemi YA. Endothelial nitric oxide synthase gene Glu298Asp polymorphism and blood pressure, left 
ventricular mass and carotid artery atherosclerosis in a population-based cohort. J Intern Med 2002; 
251:102-110. 
W86. Schmoelzer I, Renner W, Paulweber B, Malaimare L, Iglseder B, Schmid P, Schallmoser K, 
Wascher TC. Lack of association of the Glu298Asp polymorphism of endothelial nitric oxide synthase with 
manifest coronary artery disease, carotid atherosclerosis and forearm vascular reactivity in two Austrian 
populations. Eur J Clin Invest 2003; 33:191-198. 
W87. Paradossi U, Ciofini E, Clerico A, Botto N, Biagini A, Colombo MG. Endothelial function and 
carotid intima-media thickness in young healthy subjects among endothelial nitric oxide synthase 
Glu298Asp and T-786C polymorphisms. Stroke 2004; 35:1305-1309. 
W88. Czarnecka D, Kawecka-Jaszcz K, Stolarz K, Olszanecka A, Dembinska-Kiec A, Kiec-Wilk B. 
Ambulatory blood pressure, left ventricular mass and vascular phenotypes in relation to the endothelial 
 at UNIVERSITY EDINBURGH on June 11, 2013circgenetics.ahajournals.orgDownloaded from 
nitric oxide synthase gene Glu298Asp and intron 4 polymorphisms in a population-based family study. J 
Hum Hypertens 2005; 19:413-420. 
W89. Spoto B, Benedetto FA, Testa A, Tripepi G, Mallamaci F, Maas R, Boeger RH, Zoccali C, 
Parlongo RM, Pisano A. Atherosclerosis and the Glu298Asp polymorphism of the eNOS gene in white 
patients with end-stage renal disease. Am J Hypertens 2005; 18:1549-1555. 
W90. Wolff B, Braun C, Schluter C, Grabe HJ, Popowski K, Volzke H, Ludemann J, John U, Cascorbi I. 
Endothelial nitric oxide synthase Glu298Asp polymorphism, carotid atherosclerosis and intima-media 
thickness in a general population sample. Clin Sci 2005; 109:475-481. 
W91. Lekakis JP, Ikonomidis I, Tsibida M, Protogerou A, Papada A, Papapanagiotou A, Revela I, 
Papamichael CM, Kalofoutis AT, Kremastinos DT. Genetic variations of the endothelial nitric oxide 
synthase gene are related to increased levels of C-reactive protein and macrophage-colony stimulating-
factor in patients with coronary artery disease. Thromb Haemost 2006; 96:520-528. 
W92. Bhuiyan A, Chen W, Srinivasan S, Rice J, Mock N, Tang R, Bond M, Boerwinkle E, Berenson G. 
Influence of nitric oxide synthase gene polymorphism (G894T) on carotid artery intima-media thickness in 
adults: the Bogalusa Heart Study. J Am Soc Hypertens 2007; 1:362-368. 
W93. Castellano M, Barlassina C, Muiesan ML, Beschi M, Cinelli A, Rossi F, Rizzoni D, Cusi D, Gabiti-
Rosei E. Alpha-adducin gene polymorphism and cardiovascular phenotypes in a general population. J 
Hypertens 1997; 15:1707-1710. 
W94. Sarzani R, Cusi D, Salvi F, Barlassina C, Macciardi F, Pietrucci F, Cola G, Catalini R, Dal Fiume 
C, Dessi-Fulgheri P, Rappelli A. The 460Trp allele of a-adducin increases carotid intima-media thickness 
in young adult males. J Hypertens 2006; 24:697-703. 
W95. W95.     Yazdanpanah M, Sayed-Tabatabaei FA, Hofman A, Aulchenko YS, Oostra BA, Stricker 
BHC, Pols HAP, Lamberts SWJ, Witteman JCM, Janssen JAMJ, Van Duijn CM. The a-adducin gene is 
associated with macrovascular complications and mortality in patients with type 2 diabetes. Diabetes 
2006; 55:2922-2927. 
 
 
 at UNIVERSITY EDINBURGH on June 11, 2013circgenetics.ahajournals.orgDownloaded from 
